C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 291, Issue , 2016, Pages 54-58

  Moriguchi, Kota ^a,b   Miyamoto, Katsuichi ^c   Tanaka, Noriko ^c   Ueno, Rino ^c   Nakayama, Takashi ^d   Yoshie, Osamu ^c   Kusunoki, Susumu ^c  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Self Defense Force Hanshin Hospital   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KINKI UNIVERSITY   (Japan)

Author keywords

Chemokine receptor; Experimental autoimmune encephalomyelitis

Indexed keywords

CHEMOKINE RECEPTOR CCR4 ANTAGONIST; COMPOUND 22; UNCLASSIFIED DRUG; 2-(3-HYDROXY-4,5-DIIODO-6H-6-OXOXANTHEN-9-YL)BENZOIC ACID; CCR4 PROTEIN, MOUSE; CHEMOKINE RECEPTOR CCR4; CYTOKINE; FLUORESCEIN DERIVATIVE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; CHEMICALLY INDUCED; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; T LYMPHOCYTE; TIME FACTOR;

ANIMALS; CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLUORESCEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; RECEPTORS, CCR4; T-LYMPHOCYTES; TIME FACTORS;

EID: 84959358996     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.12.011     Document Type: Article

References (9)

1. ClinicalTrials.gov A study to assess the effects of MK0812 on disease activity in patients with relapsing-remitting multiple sclerosis as measured by magnetic resonance imaging (MRI) 2005, (NCT00239655. Available from https://clinicaltrials.gov/ct2/show/record/NCT00239655).
2. Comerford I., Kara E.E., McKenzie D.R., McColl S.R. Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking. Br. J. Hematol. 2013, 164:329-341.
3. -/- mice. Susceptibility in multiple strains. Am. J. Pathol. 2003, 162:139-150.
4. Ghorban K., Dadmanesh M., Hassanshahi G., Momeni M., Zare-Bidaki M., Arababadi M.K., et al. Is the CCR5 δ 32 mutation associated with immune system-related diseases?. Inflammation 2013, 36:633-642.
5. Kaminuma O., Ohtomo T., Mori A., Nagakubo D., Hieshima K., Ohmachi Y., et al. Selective down-regulation of Th2 cell-mediated airway inflammation in mice by pharmacological intervention of CCR4. Clin Exp Allergy. 2012, 42:315-325.
6. Miyamoto K., Miyake S., Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001, 413:531-534.
7. Moriguchi K., Miyamoto K., Tanaka N., Yoshie O., Kusunoki S. The importance of CCR4 and CCR6 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2013, 257:53-58.
8. Purandare A.V., Wan H., Somerville J.E., Burke C., Vaccaro W., Yang X.X., et al. Core exploration in optimization of chemokine receptor CCR4 antagonists. Bioorg. Med. Chem. Lett. 2007, 17:679-682.
9. Wang Y., Cui L., Gonsiorek W., Min S.H., Anilkumar G., Rosenbulm S., et al. CCR2andCXCR4regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis. J. Inflamm. 2009, 6:32.